West Pharmaceutical Services, Inc., commonly referred to as West, is a leading provider of innovative solutions for injectable drug delivery and containment. Headquartered in the United States, West operates extensively across major regions, including Europe and Asia, serving a global clientele in the pharmaceutical and biotechnology industries. Founded in 1923, the company has achieved significant milestones, including advancements in drug delivery systems and the development of high-quality packaging solutions. West's core offerings include a range of primary packaging components, delivery systems, and contract manufacturing services, all designed to enhance the safety and efficacy of medications. What sets West apart is its commitment to quality and innovation, ensuring that its products meet the stringent demands of the healthcare sector. With a strong market position and a reputation for excellence, West continues to be a trusted partner for pharmaceutical companies worldwide.
How does West Pharmaceutical Services's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
West Pharmaceutical Services's score of 40 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, West Pharmaceutical Services reported total carbon emissions of approximately 97,903,000 kg CO2e. This figure reflects their ongoing commitment to sustainability within the pharmaceutical sector. In 2023, their emissions were broken down into Scope 1 and Scope 2, with Scope 1 emissions at about 30,828,000 kg CO2e and Scope 2 emissions at approximately 73,362,000 kg CO2e, resulting in a combined total of about 104,190,000 kg CO2e for those two scopes. West Pharmaceutical Services has set ambitious reduction targets, aiming to decrease absolute emissions by 10% for both Scope 1 and Scope 2 from 2019 to 2023. Additionally, they have committed to a more significant reduction of 40% in absolute emissions across all scopes by 2030, with a focus on achieving 50% renewable electricity and improving energy efficiency by 3% annually. The company has demonstrated a proactive approach to climate commitments, although specific data on Scope 3 emissions remains undisclosed. Their initiatives align with industry standards for climate action, reflecting a commitment to reducing their environmental impact while maintaining operational efficiency.
Access structured emissions data, company-specific emission factors, and source documents
2011 | 2015 | 2019 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|
Scope 1 | 28,699,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | - | - | 000,000,000 | - | 00,000,000 | 00,000,000 |
Scope 3 | 118,243,000 | 000,000,000 | - | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
West Pharmaceutical Services is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.